BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 9044848)

  • 1. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines.
    Selcer KW; Hegde PV; Li PK
    Cancer Res; 1997 Feb; 57(4):702-7. PubMed ID: 9044848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors.
    Kolli A; Chu GH; Rhodes ME; Inoue K; Selcer KW; Li PK
    J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):31-40. PubMed ID: 10215035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of potent non-estrogenic estrone sulfatase inhibitors.
    Li PK; Chu GH; Guo JP; Peters A; Selcer KW
    Steroids; 1998; 63(7-8):425-32. PubMed ID: 9654650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives.
    Selcer KW; Jagannathan S; Rhodes ME; Li PK
    J Steroid Biochem Mol Biol; 1996 Sep; 59(1):83-91. PubMed ID: 9009241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase.
    Woo LW; Howarth NM; Purohit A; Hejaz HA; Reed MJ; Potter BV
    J Med Chem; 1998 Mar; 41(7):1068-83. PubMed ID: 9544207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: x-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)-estratriene.
    Hejaz HA; Purohit A; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 1999 Aug; 42(16):3188-92. PubMed ID: 10447965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of novel steroid sulfatase inhibitors; II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats.
    Saito T; Kinoshita S; Fujii T; Bandoh K; Fuse S; Yamauchi Y; Koizumi N; Horiuchi T
    J Steroid Biochem Mol Biol; 2004 Feb; 88(2):167-73. PubMed ID: 15084348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stilbene-based inhibitors of estrone sulfatase with a dual mode of action in human breast cancer cells.
    Walter G; Liebl R; von Angerer E
    Arch Pharm (Weinheim); 2004 Dec; 337(12):634-44. PubMed ID: 15597397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer.
    Duncan L; Purohit A; Howarth NM; Potter BV; Reed MJ
    Cancer Res; 1993 Jan; 53(2):298-303. PubMed ID: 8417823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors.
    Li PK; Milano S; Kluth L; Rhodes ME
    J Steroid Biochem Mol Biol; 1996 Sep; 59(1):41-8. PubMed ID: 9009236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
    Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
    Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
    Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCF-7 and T-47D, and the hormone-independent MDA-MB-231, breast cancer cell lines.
    Chetrite GS; Kloosterboer HJ; Philippe JC; Pasqualini JR
    Anticancer Res; 1999; 19(1A):269-75. PubMed ID: 10226553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor.
    Purohit A; Woo LW; Singh A; Winterborn CJ; Potter BV; Reed MJ
    Cancer Res; 1996 Nov; 56(21):4950-5. PubMed ID: 8895749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-phenylindole sulfamates: inhibitors of steroid sulfatase with antiproliferative activity in MCF-7 breast cancer cells.
    Walter G; Liebl R; von Angerer E
    J Steroid Biochem Mol Biol; 2004 Apr; 88(4-5):409-20. PubMed ID: 15145451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship studies of the amide functionality in (p-O-sulfamoyl)-N-alkanoyl tyramines as estrone sulfatase inhibitors.
    Chu GH; Milano S; Kluth L; Rhodes M; Boni R; Johnson DA; Li PK
    Steroids; 1997 Jul; 62(7):530-5. PubMed ID: 9253792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of steryl sulfatase activity in LNCaP human prostate cancer cells.
    Selcer KW; Kabler H; Sarap J; Xiao Z; Li PK
    Steroids; 2002 Sep; 67(10):821-6. PubMed ID: 12231117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells.
    Utsumi T; Leese MP; Chander SK; Gaukroger K; Purohit A; Newman SP; Potter BV; Reed MJ
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):219-27. PubMed ID: 15862969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of oestrone sulphatase activity in the MDA-MB-231 breast cancer cell line by breast cyst fluid from Malaysian women.
    Elsadig RE; Reimann K; Yip CH; Lai LC
    Anticancer Res; 2001; 21(4A):2693-6. PubMed ID: 11724341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.